
Eli Lilly’s once-weekly diabetes candidate dulaglutide has matched Novo Nordisk’s established once-daily Victoza (liraglutide) when it comes to lowering blood …

New clinical trial results have shown Lilly’s investigational type 2 diabetes drug has beaten its three nearest rivals in reducing …

Eli Lilly and Co’s new type II diabetes candidate dulaglutide – which it intends to file this year – has …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

